Primary malignant melanoma of the parotid gland: a case report.

Q2 Medicine
Archives of Craniofacial Surgery Pub Date : 2026-02-01 Epub Date: 2026-02-20 DOI:10.7181/acfs.2025.0077
Maria Alabdulaal, Zainab Alshuhayb, Dinah AlNoaimi, Sarah AlQahtani, Ijaz Saud, Alaa A Salim
{"title":"Primary malignant melanoma of the parotid gland: a case report.","authors":"Maria Alabdulaal, Zainab Alshuhayb, Dinah AlNoaimi, Sarah AlQahtani, Ijaz Saud, Alaa A Salim","doi":"10.7181/acfs.2025.0077","DOIUrl":null,"url":null,"abstract":"<p><p>Primary malignant melanoma of the parotid gland (PMMPG) is an exceptionally rare neoplasm, comprising less than 0.7% of all parotid malignancies and often mistaken for metastatic melanoma. This case presents a 66-year-old man with a painless, slowly enlarging right parotid mass. Imaging revealed a lesion localized to the superficial parotid lobe with FDG (fluorodeoxyglucose)-avid level II lymph nodes. Fine-needle aspiration suggested melanoma, confirmed by immunohistochemistry. The patient underwent total parotidectomy, neck dissection, adjuvant radiotherapy and immunotherapy with pembrolizumab under ongoing oncologic surveillance. Histopathology confirmed melanoma with nodal metastasis and negative margins, with no evidence of local recurrence at 6-month follow-up. Diagnosis of PMMPG demands exclusion of other primary sites and prior excision history, making immunohistochemistry essential. Treatment typically involves surgical resection and radiotherapy; however, prognosis remains poor due to high recurrence and metastasis rates. PMMPG requires a coordinated, multidisciplinary approach. Although aggressive intervention offers the best outcomes, the long-term prognosis is limited. Continued research is essential, particularly focusing on molecular differentiation from clear cell sarcoma and the identification of specific molecular markers that can guide targeted therapy.</p>","PeriodicalId":52238,"journal":{"name":"Archives of Craniofacial Surgery","volume":"27 1","pages":"40-44"},"PeriodicalIF":0.0000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12968647/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Craniofacial Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7181/acfs.2025.0077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Primary malignant melanoma of the parotid gland (PMMPG) is an exceptionally rare neoplasm, comprising less than 0.7% of all parotid malignancies and often mistaken for metastatic melanoma. This case presents a 66-year-old man with a painless, slowly enlarging right parotid mass. Imaging revealed a lesion localized to the superficial parotid lobe with FDG (fluorodeoxyglucose)-avid level II lymph nodes. Fine-needle aspiration suggested melanoma, confirmed by immunohistochemistry. The patient underwent total parotidectomy, neck dissection, adjuvant radiotherapy and immunotherapy with pembrolizumab under ongoing oncologic surveillance. Histopathology confirmed melanoma with nodal metastasis and negative margins, with no evidence of local recurrence at 6-month follow-up. Diagnosis of PMMPG demands exclusion of other primary sites and prior excision history, making immunohistochemistry essential. Treatment typically involves surgical resection and radiotherapy; however, prognosis remains poor due to high recurrence and metastasis rates. PMMPG requires a coordinated, multidisciplinary approach. Although aggressive intervention offers the best outcomes, the long-term prognosis is limited. Continued research is essential, particularly focusing on molecular differentiation from clear cell sarcoma and the identification of specific molecular markers that can guide targeted therapy.

Abstract Image

Abstract Image

Abstract Image

原发性腮腺恶性黑色素瘤1例报告。
原发性腮腺恶性黑色素瘤(PMMPG)是一种非常罕见的肿瘤,占所有腮腺恶性肿瘤的不到0.7%,常被误认为转移性黑色素瘤。本病例为66岁男性,右侧腮腺肿块缓慢增大,无痛。影像学显示病变局限于腮腺浅叶伴FDG(氟脱氧葡萄糖)- II级淋巴结。细针穿刺提示黑色素瘤,免疫组织化学证实。在持续的肿瘤监测下,患者接受了腮腺全切除术、颈部清扫、辅助放疗和派姆单抗免疫治疗。组织病理学证实黑色素瘤伴淋巴结转移和阴性边缘,6个月随访无局部复发证据。诊断PMMPG需要排除其他原发部位和既往切除史,因此免疫组织化学是必要的。治疗通常包括手术切除和放疗;然而,由于高复发和转移率,预后仍然很差。PMMPG需要协调的多学科方法。虽然积极的干预提供了最好的结果,长期预后是有限的。持续的研究是必要的,特别是关注透明细胞肉瘤的分子分化和可以指导靶向治疗的特定分子标记物的鉴定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archives of Craniofacial Surgery
Archives of Craniofacial Surgery Medicine-Otorhinolaryngology
CiteScore
2.90
自引率
0.00%
发文量
44
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书